Travere Therapeutics Inc (TVTX)

Sector:
MATERIALS
Industry:
CHEMICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Eric M. Dube
Employees:
460
3611 VALLEY CENTRE DR SUITE 300, SAN DIEGO, CA 92130
888-969-7879

Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

Data derived from most recent annual or quarterly report
Market Cap 441.814 Million Shares Outstanding75.011 Million Avg 30-day Volume 1.548 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.09
Price to Revenue5.1642 Debt to Equity3.2906 EBITDA-270.714 Million
Price to Book Value10.0218 Operating Margin-136.9637 Enterprise Value1.059 Billion
Current Ratio3.994 EPS Growth-0.235 Quick Ratio3.771
1 Yr BETA 1.084 52-week High/Low 23.18 / 5.25 Profit Margin-136.0029
Operating Cash Flow Growth-181.3193 Free Cash Flow to Firm (FCFF) TTM -239.649 Million Free Cash Flow to Equity (FCFE) TTM-216.728 Million
Altman Z-Score-1.5427
Earnings Report2024-02-22
View SEC Filings from TVTX instead.

View recent insider trading info

Travere Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TVTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TVTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-10-04 by HEERMA PETER
  • 4: filed on 2023-09-05 by CLINE CHRISTOPHER R.
  • 4: filed on 2023-09-05 by ROTE WILLIAM E.
  • 4: filed on 2023-09-05 by DUBE ERIC M
  • 4: filed on 2023-05-19 by BAYNES ROY D.
  • 4: filed on 2023-05-19 by POOLE SANDRA
  • 4: filed on 2023-05-19 by WILLIAMS BRINKLEY RUTH
  • 4: filed on 2023-05-19 by MECKLER JEFFREY A
  • 4: filed on 2023-05-19 by ORWIN JOHN A
  • 4: filed on 2023-05-19 by LYONS GARY A

    • Events (8k)

  • 8-K: filed on 2023-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-21:
    Item 8.01: Other Events
  • 8-K/A: filed on 2023-09-07:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-05:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-31:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-09-05:
  • 144: filed on 2023-05-10:
  • 144: filed on 2023-05-10:
  • 144: filed on 2023-09-05:
  • 144: filed on 2023-09-05:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    3.1 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HEERMA PETER CHIEF COMMERCIAL OFFICER

    • Officer
    		 80,257 2023-10-03 3

    CLINE CHRISTOPHER R. CHIEF FINANCIAL OFFICER

    • Officer
    		 50,574 2023-09-05 5

    REED ELIZABETH E SVP, GC & CORPORATE SECRETARY

    • Officer
    		 58,096 2023-08-31 4

    ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D

    • Officer
    		 61,173 2023-08-31 4

    DUBE ERIC M CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 242,595 2023-08-31 4

    LYONS GARY A

    • Director
    		 44,500 2023-05-17 1

    WILLIAMS BRINKLEY RUTH

    • Director
    		 12,750 2023-05-17 1

    COUGHLIN TIMOTHY

    • Director
    		 42,500 2023-05-17 1

    SQUARER RON

    • Director
    		 22,375 2023-05-17 1

    ORWIN JOHN A

    • Director
    		 22,375 2023-05-17 1

    MECKLER JEFFREY A

    • Director
    		 74,500 2023-05-17 1

    BRUHN SUZANNE LOUISE

    • Director
    		 15,750 2023-05-17 1

    POOLE SANDRA

    • Director
    		 17,000 2023-05-17 1

    BAYNES ROY D.

    • Director
    		 24,500 2023-05-17 1

    CALVIN SANDRA SVP, CHIEF ACCOUNTING OFFICER

    • Officer
    		 42,247 2023-05-10 3

    INRIG JULA CHIEF MEDICAL OFFICER

    • Officer
    		 37,757 2023-01-31 2

    ASELAGE STEVE

    • Director
    		 146,919 2022-05-11 0

    CLAGUE LAURA CHIEF FINANCIAL OFFICER

    • Officer
    		 35,655 2022-05-10 0

    ROSENBERG NOAH L. CHIEF MEDICAL OFFICER

    • Officer
    		 47,614 2021-08-13 0

    MCFARLANE NEIL F. CHIEF OPERATING OFFICER

    • Officer
    		 26,988 2019-05-15 0

    KOZARICH JOHN W

    • Director
    		 29,000 2019-05-08 0

    SHIH ALVIN EVP OF RESEARCH & DEVELOPMENT

    • Officer
    		 158,334 2016-09-01 0

    GOLDING CORNELIUS E

    • Director
    		 29,000 2016-05-18 0

    VALEUR JENSEN MARGARET E GENERAL COUNSEL

    • Officer
    		 100,000 2016-02-01 0

    BROADFIN HEALTHCARE MASTER FUND LTD

    BROADFIN CAPITAL, LLC

    KOTLER KEVIN

    • 10% Owner
    		 2,658,854 2015-01-13 0

    PLOTKIN HORACIO CHIEF MEDICAL OFFICER

    • Officer
    		 91,767 2014-12-12 0

    RICHARDSON STEVEN GARY

    • Director
    		 129,165 2014-11-21 0

    SHKRELI MARTIN

    • FMR OFFICER DIR 10% SHAREHLDR
    		 No longer subject to file 2014-11-14 0

    PALEY JEFFREY

    • Director
    		 51,665 2014-08-14 0

    PANOFF MARC L CHIEF FINANCIAL OFFICER

    • Officer
    		 221,100 2014-02-24 0

    OPALEYE GP LLC

    • 10% Owner
    		 2,097,671 2013-12-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HEERMA PETER - Officer CHIEF COMMERCIAL OFFICER

    		2023-10-04 16:05:09 -0400 2023-10-03 S 3,091 $8.25 d 80,257 direct -3.7975 -12.0253 -23.9241 0.0 1 -31.1392 26

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TRAVERE THERAPEUTICS INC TVTX 2023-11-28 12:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 22:15:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 21:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 21:15:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 20:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 20:15:05 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 19:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 19:15:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 18:45:05 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 18:15:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 17:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 17:15:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 16:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 16:15:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 15:45:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 15:15:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 14:45:03 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 14:15:04 UTC 5.07 0.25 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 13:45:04 UTC 4.8598 0.4602 1900000
    TRAVERE THERAPEUTICS INC TVTX 2023-11-27 13:15:04 UTC 4.8598 0.4602 1900000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund TVTX -10028.0 shares, $-143199.84 2023-08-31 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio TVTX -31.0 shares, $-277.14 2023-09-30 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund TVTX -23486.0 shares, $-209964.84 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments